- Evotec SE has announced a new Gates Foundation grant for its subsidiary Just – Evotec Biologics to expand use of the J.MD™ molecular design platform.
- The funding will support ten new projects over three years to improve affordability and access to monoclonal antibodies for global health.
Evotec SE has announced that its Seattle-based subsidiary, Just – Evotec Biologics, has received a new grant from the Gates Foundation. The funding will support global access to biotherapeutics by applying the subsidiary’s J.MD™ Molecular Design service to reduce development costs and improve manufacturability.
The investment will enable Just – Evotec Biologics to run ten new J.MD™ projects over the next three years. These projects will focus on the development of biotherapeutics targeting multiple global health disease indications, with an emphasis on improving developability and lowering the cost of goods for monoclonal antibodies.
Under the grant, the company will use its J.MD™ service, a component of the J.DESIGN™ platform, which integrates computational technologies and high-throughput methods to optimise molecular design at early development stages. The approach is intended to improve stability, manufacturability and efficacy, while reducing risks such as immunogenicity and instability.
The award extends a collaboration between Just – Evotec Biologics and the Gates Foundation that began in 2014. Since then, the company has delivered multiple cGMP manufacturing campaigns for monoclonal antibodies targeting respiratory syncytial virus, malaria and HIV, supporting broader efforts to expand access to biologics in low- and middle-income countries.
“We are thrilled to receive this new grant from the Gates Foundation which will strengthen our commitment to reducing the cost of biologics development to expand global access.”
Dr Linda Zuckerman, EVP and Global Head of Just – Evotec Biologics
